Atypical Endometrial Hyperplasia Clinical Trial
Official title:
Comparing Metformin Plus Megestrol Acetate With Megestrol Acetate Alone as a Fertility-sparing Treatment in Patients With Atypical Endometrial Hyperplasia
To verify whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH).
Whether metformin could improve the effect of progestin as fertility-sparing treatment in patients with atypical endometrial hyperplasia(AEH) is still not clear. Our previous finding from subgroup analysis in a phase II randomized controlled trial showed that 39.6% of AEH patients in metformin plus megestrol acetate group achieved complete response, compared with 20.4% in group of megestrol acetate alone. This trial aim to fully testify the effect of metformin in fertility-sparing treatment for AEH patients with adequate sample size. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02397083 -
Levonorgestrel-Releasing Intrauterine System With or Without Everolimus in Treating Patients With Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer
|
Phase 2 | |
| Recruiting |
NCT05647109 -
Patient-derived Tumor-like Cell Clusters Predict Progesterone Sensitivity in Patients With Early Endometrial Cancer
|
||
| Completed |
NCT04491682 -
Megestrol Acetate Plus Rosuvastatin in Young Women With Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT00788671 -
Levonorgestrel-Releasing Intrauterine System in Treating Patients With Complex Atypical Hyperplasia or Grade I Endometrial Cancer
|
Phase 2 | |
| Completed |
NCT04385667 -
LVN- IUS Versus Oral Megesterol Acetate in Treatment of Atypical Endometrial Hyperplasia
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT01943058 -
Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer
|
Phase 2 | |
| Withdrawn |
NCT04683237 -
Liraglutide Plus Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
| Completed |
NCT00483327 -
Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol Acetate
|
Phase 2 | |
| Recruiting |
NCT05316493 -
Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
| Completed |
NCT03241888 -
Megestrol Acetate Plus LNG-IUS in Young Women With Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05316935 -
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06390904 -
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients
|
Phase 2/Phase 3 | |
| Recruiting |
NCT06379113 -
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05172999 -
Loxenatide Plus LNG-IUS in Endometrial Atypical Hyperplasia
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05675787 -
Medroxyprogesterone Acetate Plus Atorvastatin in Young Women With Early Endometrial Carcinoma and Atypical Endometrial Hyperplasia
|
Phase 2 | |
| Active, not recruiting |
NCT03671811 -
Megestrol Acetate With or Without Pterostilbene in Treating Patients With Endometrial Cancer Undergoing Hysterectomy
|
Phase 2 | |
| Completed |
NCT00490087 -
Resectoscopic Treatment of Atypical Endometrial Polyps in Fertile Women
|
Phase 3 | |
| Recruiting |
NCT05051722 -
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
|
||
| Active, not recruiting |
NCT00892866 -
CA-IX, p16, Proliferative Markers, and HPV in Diagnosing Cervical Lesions in Patients With Abnormal Cervical Cells
|
N/A | |
| Recruiting |
NCT03463252 -
Value of LNG-IUS as Fertility-preserving Treatment of EAH and EC
|
Phase 2/Phase 3 |